News
Uric Acid-Lowering Therapy May Increase Risk for CKD
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
Regular users may be at risk for serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy
Hemoglobin levels lower, erythropoietin stimulating agent use higher, even for water lead levels below EPA threshold for regulatory action
Risk for hip fracture increased with EPO doses of 50 to 149, 150 to 299, and 300 or greater vs <50 units/kg/week